ADMA Biologics (NASDAQ:ADMA) Reaches New 12-Month High at $4.03

ADMA Biologics, Inc. (NASDAQ:ADMA – Get Rating) reached a new 52-week high during trading on Friday . The company traded as high as $4.03 and last traded at $4.02, with a volume of 877973 shares traded. The stock had previously closed at $3.96.

Analysts Set New Price Targets

ADMA has been the topic of a number of recent research reports. StockNews.com initiated coverage on shares of ADMA Biologics in a research report on Thursday, March 16th. They set a “sell” rating on the stock. HC Wainwright reissued a “buy” rating and set a $4.50 target price on shares of ADMA Biologics in a research report on Wednesday, February 8th.

ADMA Biologics Stock Up 6.6 %

The stock has a market capitalization of $937.50 million, a price-to-earnings ratio of -12.41 and a beta of 0.91. The firm’s fifty day moving average is $3.33 and its 200-day moving average is $3.38. The company has a debt-to-equity ratio of 1.01, a current ratio of 6.89 and a quick ratio of 2.73.

ADMA Biologics (NASDAQ:ADMA – Get Rating) last posted its quarterly earnings results on Thursday, March 23rd. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). The firm had revenue of $49.98 million for the quarter, compared to analysts’ expectations of $49.02 million. ADMA Biologics had a negative net margin of 42.77% and a negative return on equity of 47.99%. During the same period in the prior year, the company posted ($0.09) earnings per share. On average, sell-side analysts predict that ADMA Biologics, Inc. will post -0.14 earnings per share for the current year.

Institutional Trading of ADMA Biologics

Several institutional investors have recently added to or reduced their stakes in ADMA. JPMorgan Chase & Co. increased its stake in ADMA Biologics by 360.0% during the first quarter. JPMorgan Chase & Co. now owns 79,106 shares of the biotechnology company’s stock valued at $144,000 after purchasing an additional 61,909 shares during the last quarter. Raymond James & Associates increased its stake in ADMA Biologics by 24.0% during the first quarter. Raymond James & Associates now owns 199,984 shares of the biotechnology company’s stock valued at $366,000 after purchasing an additional 38,715 shares during the last quarter. Bank of New York Mellon Corp increased its stake in ADMA Biologics by 79.6% during the first quarter. Bank of New York Mellon Corp now owns 83,401 shares of the biotechnology company’s stock valued at $153,000 after purchasing an additional 36,967 shares during the last quarter. Bank of Montreal Can bought a new stake in ADMA Biologics during the first quarter valued at $1,665,000. Finally, BlackRock Inc. increased its stake in ADMA Biologics by 0.8% during the first quarter. BlackRock Inc. now owns 4,107,382 shares of the biotechnology company’s stock valued at $7,517,000 after purchasing an additional 31,791 shares during the last quarter. Institutional investors own 71.17% of the company’s stock.

ADMA Biologics Company Profile

(Get Rating)

ADMA Biologics, Inc operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations.